Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: February 14, 2018
Subject: Submission of landmark IMPACT study data to the European Medicines Agency (EMA) to support an expanded label for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD).
Key Financial Metrics
This filing is a regulatory announcement regarding clinical data submission and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Operational Updates
- Regulatory Submission: GSK and partner Innoviva, Inc. submitted a Type II variation to the EMA based on the IMPACT study to expand the label for Trelegy Ellipta.
- Study Findings: The IMPACT study demonstrated that Trelegy Ellipta was superior to dual therapies (Relvar/Breo and Anoro) on clinically important endpoints, including reducing exacerbations and improving lung function and quality of life.
- Study Scope: The IMPACT study enrolled 10,355 patients across 37 countries and is the first to directly compare three common COPD combination treatment classes using the same dose and inhaler.
- US Status: A supplemental New Drug Application (sNDA) for the expanded label is currently under review by the US Food and Drug Administration (FDA).
Guidance, Outlook, and Risks
Management Commentary: GSK leadership expressed confidence in Trelegy Ellipta as an effective treatment option for COPD patients requiring triple therapy, noting the submission clarifies the patient population most likely to benefit.
Risks and Contingencies:
- Regulatory Approval: The expanded label is contingent upon approval by the EMA and FDA; no guarantee of approval is provided.
- Safety Profile: Important safety information includes contraindications for asthma, risks of paradoxical bronchospasm, cardiovascular effects (e.g., arrhythmias), systemic steroid effects, and increased incidence of pneumonia.
- Forward-Looking Statements: Both GSK and Innoviva caution that projections regarding regulatory and commercial plans are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the status of the EMA Type II variation and the FDA sNDA for Trelegy Ellipta.
- Review the full IMPACT study data presentation at upcoming scientific meetings for detailed efficacy endpoints.
- Monitor regulatory decisions regarding the expanded indication for patients at risk of exacerbation.
- Assess the commercial impact of the expanded label on GSK's respiratory portfolio revenue.
- Review Innoviva's royalty revenue structure and economic interest in future payments related to Trelegy Ellipta.